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Background/aim: After allogeneic hematopoietic stem cell transplantation (allo-HSCT), donor natural killer (NK) cells trigger
alloreactions against potential recipient cells by their killer immunoglobulin-like receptors (KIRs). This study investigated whether
KIR/HLA genotypes and KIR haplotypes of donors and recipients exhibit a critical function in the prevalence of acute graft-versus-host
disease (aGVHD) and persistence of the graft after HLA-identical sibling allo-HSCT for patients with hematological malignancies.
Materials and methods: We studied KIR and HLA genotypes in 115 related donors and recipients (56 patients with AML and 59
patients with ALL) who had received allo-HSCT from HLA-matched sibling donors. We evaluated 17 KIR genes and some alleles,
including their ligands, using the PCR-SSP assay.
Results: KIR gene frequency results between donors and recipients showed that donors had more activating KIR than their recipients.
Chi-square comparison of KIR genotype frequencies in donors versus recipients revealed a significant difference (P < 0.001). We found
a survival association between the donor lacking and the recipient having group B KIR haplotypes, although this was not statistically
significant.
Conclusion: This study suggests that we could exploit NK cell alloreactivity as a part of the optimization of donor selection and potential
immunotherapeutic regimens to help facilitate good engraftment and reduce the risk of aGVHD incidence after allo-HSCT.
Key words: KIR, HLA, allogeneic hematopoietic stem cell transplantation, graft-versus-host disease

1. Introduction
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is the definitive choice for treatment of highrisk hematologic malignancies, even in advanced stages
(1,2). There is evidence that allogeneic HLA-matched
transplantation for patients with lymphoblastic and
myeloblastic leukemia is more effective than autogeneic
transplantation, because allo-HSCT may induce the graftversus-leukemia (GVL) effect (3,4). The potential benefit
of the GVL effect relies on the elimination of residual
malignant cells through immunological antitumor
effects, induced by alloreactive T and natural killer (NK)
cells, which leads to a lower relapse rate in allo-HSCT

patients with hematologic malignancies (3,5,6). Despite
all the advantages of allo-HSCT, there are still some
complications that limit the success of this important
procedure, including the development of graft-versushost disease (GVHD) (7). Alloreactive cells in the graft
are widely considered to mediate both the GVL effect and
GVHD (8).
Acute GVHD, a major source of morbidity in HSCT, is
mediated by donor allogeneic cytotoxic T cells against host
tissues and leads to the recruitment of other effector cells
including NK cells (9,10). The pathophysiology of acute
GVHD has been described as a three-phase phenomenon:
activation of donor-derived T cells, effector phase through
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inflammatory immune cells, and host tissue damages
mediated by inflammation (11,12).
There are ongoing efforts to identify new immunological
targets to minimize severe GVHD and provide the GVL
effect and rebuild immunity to infections (6). In alloHSCT, NK cells have been recognized as a novel factor in
the effector system that can overcome natural alloreactive
T-cell barriers (6). Alloreactive donor NK cells facilitate
engraftment by ablating different cells including residual
leukemic cells, APCs, and T cells responsible for triggering
GVHD (4,5,13–15).
NK cells are crucial components of the innate immune
system and play an important role in early immune
protection against virus-infected cells and transformed
cells or allogeneic cells, without the need for prior
sensitization (16–18). The effector function of NK cells
depends on a balance of activating and inhibitory signals
that are transmitted via clonally distributed cell receptors,
including killer immunoglobulin-like receptors (KIRs)
for major histocompatibility complex (MHC) class I
molecules on target cells (6,18,19).
In humans, KIR genes are located on chromosome
19q13.4 and to date 15 functional genes have been
discovered. This group of tightly clustered genes contains
8 inhibitory KIR (iKIR) genes (KIR2DL1-3, 2DL5A/B,
3DL1-3), 6 activating KIR (aKIR) genes (KIR2DS1-5,
3DS1), and an unusual KIR named KIR2DL4 (encodes
receptor with both inhibitory and activating functions).
Furthermore, there are 2 pseudogenes (KIR3DP1 and
2DP1) that do not encode any receptor proteins (20,21).
A great alternation of KIR gene frequency exists among
different peoples and populations (22,23).
To date, a limited number of HLA ligands have been
described for some KIR genes (24). Specificity towards
HLA class I ligands has been demonstrated for some
iKIR receptors. KIR2DL1 interacts with HLA-Cw group
2 and KIR2DL2/2DL3 with HLA-Cw group 1 epitopes
distinguished by the amino acid lysine or asparagine at
position 80, respectively. Inhibitory receptor KIR3DL1
recognizes the HLA-Bw4 and KIR3DL2 HLA-A3/A11
epitopes (25).
Like T cells, NK cells distinguish self from nonself and
play distinct roles during alloreactivity. In vitro studies
showed that a wide variety of hematological malignancies
are susceptible to alloreactive NK cytotoxicity (26).
Functional donor NK cells are thought to play a crucial
role in the outcome of allo-HSCT, such as incidence of
GVHD, relapse, and graft rejection, based on the ‘missing
self ’ and ‘missing ligand’ hypothesis (3,5,26). Recent data
have demonstrated that signaling from the KIR receptors
is important in determining the NK cell activation in graft
outcome of allo-HSCT, particularly for leukemia patients
(9,25). Although our understanding of the role of KIRs
in HSCT has recently improved considerably, conflicting

data still persist. In order to clarify the impact of KIR
and HLA genotypes on the HLA-identical sibling HSCT
outcome, patient and donor KIR gene and KIR ligand
polymorphisms were genotyped in 115 HLA-identical
donor and recipient pairs and correlated with clinical data
in simple and multiple models.
2. Materials and methods
2.1. Patient characteristics
An aggregate of 230 donors and recipients of HSCT (115
donor/recipient pairs) was included in this study between
March 2014 and February 2016 at the Bone Marrow
Transplant Center, Shariati Hospital, Tehran. All 115
patients received HLA identical sibling donor allogeneic
bone marrow transplants for acute myelogenous leukemia
(AML) (n = 56) or acute lymphoblastic leukemia (ALL)
(n = 59). For all BMT recipients who were engrafted, a
minimal 90-day follow-up period after transplantation
was considered for risk of developing acute GVHD.
Criteria for standard grading and staging of acute GVHD
were previously reported (27). These 115 transplant pairs
were selected in a consecutive manner for patients with
AML and ALL who showed aGVHD after HSCT. Patients
received hematogenic vegetative cells from bone marrow
and peripheral blood. Graft failure was categorized based
on a decline in the absolute neutrophil count below 0.2
× 109/L for three consecutive days after HSCT. Clinical
characteristics of all patients and donors of BMT are
indicated in the Table. Sanitization of CD34+ stem
cell grafts was performed with the CliniMACS system
(Miltenyi Biotec, Auburn, CA, USA).
Peripheral blood samples from patients and donors
were obtained from HSCT pairs and gDNA was harnessed
using the phenol-chloroform procedure. All patients
provided written informed consent. The ethics and
research committee of Tehran University of Medical
Sciences approved the study.
2.2. Conditioning regimen and posttransplantation immunosuppression
All patients received intravenous adjusted-dose
cyclosporine A and methotrexate (MTX) as a GVHD
prophylaxis regimen after HSCT. The conditioning
regimen was myeloablative (MA) for HLA-matched sibling
transplantations and was determined by chemotherapy,
including busulfan and cyclophosphamide with or
without antithymocyte globulin (ATG). In 103 cases, oral
busulfan and cyclophosphamide were administered as an
adjusted conditioning regimen, while for 6 patients, the
conditioning regimen was busulfan (i.v. adjusted dose) and
cyclophosphamide (adjusted dose). Six patients received
intravenous antithymocyte globulin (ATG) plus busulfan
(oral adjusted dose) and cyclophosphamide (adjusted
dose) (Table). No patient received total body irradiation.
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Table. Patient and donor clinical characteristics of donors and recipients of HSCT.

Recipient/donor sex
no. (%)

Age, mean (range)
Graft source
no. (%)
Dose of cell infusion
(mean)/kg

Grade of aGVHD
no. (%)

AML
(n = 56)

ALL
(n = 59)

M/M

14 (25)

21 (35.6)

M/F

6 (10.7)

20 (33.9)

F/M

26 (46.4)

6 (10.15)

F/F

10 (17.85)

12 (20.3)

Patient

31 (8–63)

21 (7–36)

Donor

34 (4–61)

27 (8–51)

BM

0

3 (5.1)

PBMC

56 (100)

56 (94.9)

WBC

14.2

10.4

MNC × 108

8.3

7.9

CD3 × 10

263.3

257

CD34 × 106

4.4

4.6

I

7 (12.5)

4 (6.8)

II

12 (21.4)

8 (13.6)

III

14 (25)

10 (16.9)

IV

0 (0)

2 (3.4)

Total

33 (58.9)

24 (40.7)

8 (14.3)

8 (13.6)

ATG Bu (30) cyclophosphamide

4 (7.1)

2 (3.4)

Bu (30) cyclophosphamide

52 (92.9)

51 (86.4)

Cyclophosphamide Bu (28)

0 (0)

6 (10.2)

MTX-Cyclosporine

MTX-Cyclosporine

6

Relapse occurrence
Conditioning regimen

Non-ATG

Posttransplant immunosuppressive therapy

ALL, Acute lymphocytic leukemia; AML, acute myelogenous leukemia; F, female; M, male; CMV, cytomegalovirus; MTX,
methotrexate; MNC, mononuclear cells.

2.3. HLA and KIR genotyping
All samples were HLA typed (HLA-A, -B, and DRB1)
using a low-resolution molecular typing assay. All sibling
patients and donors were typed for the existence or lack
of 17 KIR genes that included 8 inhibitory (KIR2DL1-3,
2DL5A/B, 3DL1-3), 6 activating (KIR2DS1-5, 3DS1), and
KIR2DL4 and 2 pseudogenes (KIR2DP1 and KIR3DP1).
In essence, the defined alleles of all KIR genes were
considered in the analyses. Typing of HLA and KIR
genes was performed by employing the polymerase chain
reaction-sequence-specific primer (PCR-SSP) assay. The
amplification of KIR genes was performed with an Applied
Biosystems thermal cycler (Foster City, CA, USA) using
the Kit PCR-SSP (Olerup SSP-KIR Genotyping, Sweden),
under conditions described by the manufacturer. The KIR
ligands including the HLA-Bw4 and HLA-Cw groups
(HLA-C1 and C2) were analyzed in the groups. For typing
ligands (HLA-A, -B, -CW), a PCR-SSP kit (Olerup SSP
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KIR HLA Ligand SSP Typing, Sweden) was used. The
amplicons were electrophoresed in a 2% agarose gel and
viewed with a UV transilluminator.
2.4. Identification of group A and B haplotypes
To determine haplotypic structures, all samples were
considered following the method of Rajalingam et al.
(28). Based on the gene content, the KIR genotypes were
classified into A and B haplotypes: the A haplotype mostly
consisted of iKIR genes (KIR3DL3, 2DL1, 2DL3, 2DL4,
3DL1, and 3DL2) and also one aKIR gene (KIR2DS4). The
B haplotype was more variable, comprising the fixed gene
content of both stimulating and suppressor KIR genes
(KIR2DL5, 2DL2, 2DS1, 2DS2, 2DS3, and 2DS5) (29). The
inheritance of distinct paternal and maternal haplotypes
(A+A, A+B, or B+B) generated different KIR genotypes,
including dominant inhibitory (AA genotype), dominant
activating (BB genotype), or balanced (AB genotype). The
KIR genes can be separated into centromeric and telomeric
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gene regions, with each containing 4 genes. While the
centromeric half has KIR2DS2–2DL2–2DL5B–2DS3
genes, the telomeric half mainly consists of KIR3DS1–
2DL5A–2DS5–2DS1 genes (20). The associations of KIR
haplotypes with transplantation outcome were analyzed
by distinguishing between AA or Bx haplotypes, where x
stands for either A or B haplotype.
2.5. Statistical analysis
The relationships between genes and aGVHD and rejection
were calculated using the chi-square test. The Kaplan–
Meier algorithm was used to estimate the probability of
survival (overall survival, OS) and defined events, while
log-rank statistics provided the difference between the
survival curves of the groups. The reverted time between
the time of death and HSCT and the last recorded contact
criteria was used for defining OS in this study. The
association of clinical (transplant characteristics; Table)
and genetic variables with each outcome was evaluated
using multivariate survival analysis in a Cox regression
model. P < 0.05 and the 95% confidence interval (95% CI)
were the estimated margins for statistical significance in
each analysis. All analyses were performed with SPSS 21.0
(IBM Corp., Armonk, NY, USA).
3. Results
3.1. Patient and graft characteristics
Clinical characteristics of all HLA matched recipients and
donors of HSCT are provided in the Table. The results of
this study showed that 49.5% of patients had aGVHD and
the rate of aGVHD in the AML and ALL groups was 58.9%
and 40.7%, respectively. The incidence of grades III and
IV patients with acute GVHD (highest incidence rate of
grades) was 17.4% and 20.8%. In terms of grade, relapse
occurrence, and graft source, there was no detectable
difference between the groups. The conditioning

treatments for ALL and AML patients were almost the
same. Considering ATG treatment, we had 4 cases among
AML and 2 cases among ALL patients.
3.2. Frequencies of individual donor/recipient KIR genes
One method for determining donor NK alloreactivity
involves using gene–gene comparisons for KIR. Donors
exhibited more activating KIR than their recipients in
a comparative analysis involving individual inhibitory
and activating KIR gene frequencies between the two
groups. Hence, a significant difference was noticed in the
frequency of KIR2DS2 (71.3% in donors and 54.8% of
recipients, P = 0.002), 2DS3 (53.9% in donors and 39.1%
of recipients, P = 0.005), 2DS5 (64.3% in donors and 40%
of recipients, P =0.001), and 2DL2 (67.8% in donors and
53% of recipients, P = 0.005) (Figure 1). The analysis was
narrowed to subgroups of patients, for myeloid versus
lymphoid malignancies. When KIR gene frequencies in
donors versus recipients were compared in patients, it was
found that the frequencies of KIR2DS2, 2DS3, 2DS5, and
one (KIR2DL2) in mediating inhibitory functions were
statistically significant in patients with AML and ALL
(data not shown). No statistical difference was observed
in the number for the remaining activating and inhibitory
KIR genes in donors and recipients.
3.3. KIR genotype mismatch and donor NK alloreactivity
forecast
Discrete paternal and maternal haplotype inheritance
produces varying KIR genotypes (A+A, A+B, or B+B),
an aspect accounted for in the content of each donor and
recipient KIR gene. Genotype frequencies of AA among
the donors and recipients were 12.2% and 25.2%, while
genotype frequencies of Bx between donors and recipients
were 87.8% and 74.8%, respectively. Comparison of KIR
genotype frequencies in donors versus recipients revealed
a significant difference (P < 0.001).

Figure 1. The frequency of KIR genes in donors and recipients of HSCT.
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The distribution of each transplant to one of the
four groups depending on the donor and the recipient
KIR genotype combination was based on the donor
and recipient AA or Bx genotype. Based on the four
classifications in Figure 2, we explored the hypothesis that
differences in outcome correlate with donor–recipient KIR
genotype combination. Analysis of the overall survival
showed no significant difference in a total comparison
of all 115 patients (P = 0.350) by log-rank test (Figure 3).
The presence of group B KIR haplotypes in the recipients
and their absence in the donors had an association with
utmost survival rate. In other words, best survival was
achieved by Bx patients receiving an AA graft. By using
Cox proportional hazard modeling, the grades of GVHD
after transplantation (HR = 5.5, P = 0.043) and ATG

conditioning regimen (HR = 7.7, P = 0.019) turned out
to be prognostic factors affecting transplant survival.
None of the other analyzed potential factors like recipient
and donor characteristics, including the transplantation
method, had any impact on transplant survival.
Of the 115 patients who underwent transplantation
for AML and ALL, the incidence of aGVHD in the four
KIR genotype combinations was 42.1% (9/19) for Bxdonor/AA-recipient, 30% (3/10) for AA-donor/AArecipient, 75% (3/4) for AA donor/Bx-recipient, and
52.4% (43/82) for Bx-donor/Bx recipient. We observed
that the combination of Bx recipients given an AA graft
was a susceptible factor for occurrence of aGVHD after
transplantation for myeloid leukemia, but the study failed
to reach a statistically significant level. Figure 4 provides

Figure 2. Frequency distribution of KIR genes of patients with hematologic malignancies based on the donor and recipient KIR
genotypes. A) Donor-AA/recipient-AA: donors and patients have identical KIR gene content and KIR gene frequencies. B) Donor-AA/
recipient-Bx: recipients have more activating KIR than their donors. C) Donor-Bx/recipient-Bx: donors and recipients have almost the
same KIR gene frequencies. D) Donor-Bx/recipient-AA: donors have more activating KIR than their recipients. KIR2DL4, -3DL2, and
-3DL3 were not typed for in this panel as these genes are present in all individuals.
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Figure 3. Kaplan–Meier graft survival curve. The figure summarizes the comparison of graft survival for KIR genotypes. Kaplan–Meier
analysis of overall survival for patients with the donor-recipient KIR genotype combinations including donor-AA/recipient-AA, donorAA/recipient-Bx, donor-Bx/recipient-AA, and donor-Bx/recipient-Bx.

a comparison of hazard modeling of the different KIR
genotype combinations of the 115 patients who underwent
transplantation for leukemia.
3.4. Combinatorial analysis and its effect on posttransplantation outcome
Combinatorial analysis is a combination of recipient HLA
class I genotype with donor-recipient KIR genotypes. Due
to the HLA-C type’s significance in clinical associations, and
also its consideration as major ligands for KIR, including
beneficial NK-cell alloreactions after haploidentical
transplantation, HLA-Cw was assessed in 115 donor/
recipient pairs. Frequencies of C1, C2, and C1C2 in the
donor/recipient pairs were compared, as shown in Figure
5. However, the analyses of HLA-Cw frequencies failed to
show a statistically significant association.
The ligand incompatibility model was used to predict
NK alloreactive donors. All transplants were divided into
two groups, based on whether the recipients and their
HLA-identical donors had C2. The reason for this division
was the difference between the C1 and C2 ligands and their

cognate inhibitory KIR, which was such that C2 produced
more robust interactions than C1. Recipients lacking
C2 were assigned as C1 homozygotes (C1C1), as such
recipients having C2 included both C2C2 homozygotes
and C2Cx heterozygotes (where x stands for either C1 or
C2).
The combination of HLA-C with either the donor or
the recipient KIR genotypes when considered showed that
there was no significant relationship between genotype
ligands and aGVHD, although mean survival of recipientAA/C1C1 was lower compared with recipient-AA/C2Cx.
Thus, the combination showed increased aGVHD when
the recipient was C1C1. The highest survival rate was
observed for the combination of AA donor, AA recipient,
and C2Cx (Figure 6).
Recipient HLA-B epitopes and the association with
donor-recipient KIR genes was analyzed, since the Bw4
epitope is a robust ligand for KIR3DL1. Patients with
the four donor-recipient KIR genotype combinations
were divided according to HLA-B type. No differences
were observed in the occurrence of aGVHD irrespective
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Figure 4. Kaplan–Meier analysis of acute graft-versus-host disease (aGVHD) in AML and ALL patients (n = 115) with different KIR
genotype combinations in hazard modeling approach. Comparison of aGVHD between donor-AA/recipient-AA patients, donor-AA/
recipient-Bx, donor-Bx recipient-AA, and donor-Bx/recipient-Bx.

of whether Bw4 was present or absent in different KIR
genotype combinations.
4. Discussion
NK cells are thought to contribute to enhanced GVL
effect and improved survival after allo-HSCT in a
variety of conditions. The effect is associated with NK
cell alloreactivity in the context of transplantation and
depends on donor–recipient incompatibility regarding
NK cell receptors and their ligands (3,30,31). Variation
in gene number and sequence polymorphism influence
interindividual variability in the KIR gene family (22). The
difference in the genes and alleles may raise the question of
whether the genetic content influences susceptibility and
resistance in the occurrence of aGVHD. The present study
was undertaken to investigate whether KIR and HLA
genotypes play a crucial role in the occurrence of aGVHD
and graft survival after HLA-identical sibling allo-HSCT.
A variety of immune-related diseases have been
associated with specific KIR genotypes (22). We
hypothesized that the number of activating KIR genes may
have an improvement effect on survival after allo-HSCT.
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The comparison of KIR gene frequencies between donors
and recipients showed that donors have more activating
KIR than their recipients, as reflected in the significant
differences observed in the frequency of KIR2DS2, 2DS3,
and 2DS5. Genotypes with a greater number of aKIR genes
and a lower number of iKIR genes have been shown to be
associated with autoimmune diseases (22). In the case of
allo-HSCT, a study revealed that the presence of activating
KIR in the donor graft promoted immune sensibility;
meanwhile, the presence of repressive KIR in the recipient
promoted immune tolerance (32). Additionally, the
existence of more favorable activating KIRs as opposed to
their absence was the focal point of qualifying potential
donors based on the KIR repertoire (8). Despite the
establishment that outcome was impacted by KIRs in
a majority of cases, contradictory results prevailed.
The enhancement or depreciation of survival ensued
from donor/recipient incompatibilities and existence of
activating KIRs (30).
When the frequencies of KIR genes of all 115 patients
were compared based on the four KIR genotype sequences,
analysis of the overall survival revealed no significant

HOSEINIAN et al. / Turk J Med Sci

Figure 5. Genotype ligand frequencies between AML and ALL disease donor and recipients.

Figure 6. Influence of HLA-C and HLA-B genotype on acute graft-versus-host disease. A) Kaplan–Meier analysis of aGVHD in patients
who have been grouped according to donor-recipient KIR and recipient HLA-C genotype combination: 1) donor-AA/recipient-AA:
recipient C1; 2) donor-AA/recipient-AA: recipient C2; 3) donor-AA/recipient-Bx: recipient C1; 4) donor-AA/recipient-AA: recipient
C2; 5) donor-Bx/recipient-AA: recipient C1; 6) donor-Bx/recipient-AA: recipient C2; 7) donor-Bx/recipient-Bx: recipient C1; 8) donorBx/recipient-Bx: recipient C2. B) Kaplan–Meier analysis of aGVHD in patients who have been grouped according to donor-recipient
KIR and recipient HLA-B genotype combination: 1) donor-AA/recipient-AA: recipient BW4+; 2) donor-AA/recipient-Bx: recipient
BW4+; 3) donor-AA/recipient-Bx: recipient BW4-; 4) donor-Bx/recipient-AA: recipient BW4+; 5) donor-Bx/recipient-AA: recipient
BW4-; 6) donor-Bx/recipient-Bx: recipient BW4+; 7) donor-Bx/recipient-Bx: recipient BW4-.

difference, despite the observed inclination favoring
best survival in Bx patients receiving an AA graft. The
results showed that the combination of KIR haplotypes
in the donor and recipient could have an influence on the
outcome of HCT. However, a much bigger sample size is
necessary to get a significant result. Differences in outcome
that correlated with donor–recipient KIR genotype

combination were assessed based on four classifications.
Analysis of OS showed no significant association when
all 115 patients were compared, although Karina et al.
observed this effect in myeloid leukemia patients (32).
Giebel et al. reported that activating KIR receptor
incompatibilities enhanced graft-versus-host disease and
affected survival after allogeneic hematopoietic stem cell
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transplantation. They established that a negative patient
and a positive donor resulted in a higher risk of acute
(KIR2DS1) and chronic (KIR2DS3) GVHD including
relapse (KIR2DS5) (30).
We showed that KIR2DS3 and KIR2DS5 have
statistically different frequencies between donor and
recipient, but we found no significance for survival analysis
based on GVHD and relapse (data not shown).
In the present study, using Cox proportional hazard
modeling, we showed that grade of GVHD after the
time of transplantation and ATG conditioning regimen
were prognostic factors affecting transplant survival.
Multivariate analysis using a Cox proportional hazard
model from the findings of Yabe and Clausen suggested
that ATG preadministration was a critical factor in grade
III–IV aGVHD under consideration of the HLA-C KIR-L
status (33,34).
Donor compatibility based on the combination of
HLA and KIR data was extended to the HLA-B and
HLA-C epitope groups. In this research, genotype ligands
and aGVHD had no significant relationship, despite the
observed higher recipient-AA/C2Cx mean survival as
compared to the lower recipient-AA/C1C1. A significant
relation was reported between increased risk of aGVHD
and absent donor HLA-C2 ligand for iKIR2DL1,
including AA KIR haplotypes in patients and donors
in HLA-C1Cx (25). Another report established serious
side reactions of KIR ligand mismatch consequences on
T cell-replete unrelated HSCT in the graft-versus-host
direction. Increased incidence of aGVHD was related to
patient cognate C1 ligand and donor KIR2DS2 gene (33).
Additionally, there is evidence of the association of donor
KIR2DS1-2 positivity with a better overall outcome after
HSCT in C1-negative patients with myeloid malignancies
group (35).
Additionally, Gagne et al. reported that the
transplantation of KIR3DL1+/3DS1+ donor NK cells
into HLA-Bw4− patients without KIR3DL1/HLA-Bw4
interactions resulted in harmful outcomes (36).
In the context of unrelated cord blood transplantation,
the absence of a C-ligand (C1 or C2) of inhibitory KIR
in a patient with hematologic malignancies is associated
with lower probability of relapse, which is almost certainly
due to the GVL effect caused by NK cells of umbilical

cord blood that lack a ligand for the inhibitory KIR
2DL1/2DL2/2DL3 (37).
An increase in prevalence of aGVHD in non-T-celldepleted graft HLA-C1C1 patients has also been shown
(32). Low signal intensity during NK cell development
produces low activation potential in HLA-C1C1 and
HLA-Bw4− patients. Hence, this suggests a possible
connection between higher T-cell allogenic reaction and
NK cells, even though the exact process is still unknown.
Alternating opinions by other researchers have revealed
either a condensed aGVHD (III–IV) in HLA-C1C1 CML
patients or no influence of KIR ligands on aGVHD in
AML patients (25).
Mismatch of KIR and KIR ligands has been shown
to induce engraftment and a reduction in the outcome
of aGVHD occurrence by alloreactive donor NK cells,
which interrupts the contact between recipient APCs and
pathogenic T cells, thus suppressing aGVHD prevalence
(5). A severe increase in the T/B cell immune partitions,
possibly caused by inhibition of NK cell activity, has also
been proposed (22).
To summarize, intentional mismatch of KIR and KIR
ligands between donors and patients by clinicians in order
to utilize NK cell characteristics has led to a reduced
GVHD occurrence and higher patient survival rate after
HSCT. Even though NK cell activation might intensify
with an increase in diverse activating KIR receptor signals,
it appears that activating KIR in the donor graft induces
higher aGVHD outcomes, which are conflicting and
incomprehensible. A probable explanation could be that
donor-derived NK cells expressing activated KIRs induce
graft-to-host alloreactivity, thereby inhibiting restoration
of the immune system function. Our study results suggest
that NK alloreactivity could be considered as a rational
strategy in donor recipient allocation in order to improve
the outcome of HSCT, by potentiating the GVL effect
and reducing the aGVHD, although elucidation of the
underlying pathogenic mechanisms requires further
investigation.
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